Skip Nav Destination
.Getting the Most from Minimal Residual Disease|
November 5, 2020
Bioengineering Strategies to Phenotypically Define Minimal Residual Disease
Scott R. Manalis, PhD
Scott R. Manalis, PhD
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
Search for other works by this author on:
Blood (2020) 136 (Supplement 1): SCI2.
Citation
Scott R. Manalis; Bioengineering Strategies to Phenotypically Define Minimal Residual Disease. Blood 2020; 136 (Supplement 1): SCI2. doi: https://doi.org/10.1182/blood-2020-133039
Download citation file:
November 5 2020
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal